Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
01 2020
Historique:
pubmed: 30 7 2019
medline: 10 7 2020
entrez: 30 7 2019
Statut: ppublish

Résumé

To evaluate the prognostic impact of lymph node yield (LNY) on survival outcomes for penile squamous cell carcinoma (SCC). In all, 532 patients who underwent inguinal LN dissection (ILND) across tertiary referral centres from Europe, China, Brazil and North America were retrospectively evaluated. From this cohort, 198 patients received pelvic LND (PLND).We identified threshold values for ILND and PLND using receiver operating characteristic curves. We tested prognostic value of LNY for recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) using the Kaplan-Meir method and Cox proportional hazard regression models. The median (interquartile [IQR]) age was 59 (49-68) years and the median (IQR) follow-up after ILND was 28 (12-68.2) months. Overall, 85% of the patients had bilateral dissections. The median (IQR) number of inguinal LNs removed was 15 (10-22). Of those receiving PLND, The median (IQR) number of LNs was 13 (8-19). A LNY of ≥15 was used for dichotomisation of ILND patients, and a LNY of ≥9 was used in the PLND cohort. Patients with a LNY ≥15 had significantly better 5-year OS vs patients with a LNY <15 (70.1% vs 58.7%). On multivariable analyses, a LNY ≥15 was a predictor of OS (hazard ratio [HR] 0.68, P = 0.029). For cN0 patients, a LNY ≥15 was an independent predictor of RFS (HR 0.52, P = 0.043) and OS (HR 0.53, P = 0.021). In the PLND cohort, a LNY ≥9 was a predictor of RFS (HR 0.53, P = 0.032). Using one of the largest LND datasets to date, we found LNY to be a significant predictor of outcomes after lymphatic staging for penile SCC. Prospective validation is warranted.

Identifiants

pubmed: 31356716
doi: 10.1111/bju.14883
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

82-88

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.

Références

Arya M, Li R, Pegler K et al. Long-term trends in incidence, survival and mortality of primary penile cancer in England. Cancer Causes Control 2013; 24: 2169-76
Pizzocaro G, Algaba F, Horenblas S et al. EAU penile cancer guidelines 2009. Eur Urol 2010; 57: 1002-12
Christodoulidou M, Sahdev V, Houssein S, Muneer A. Epidemiology of penile cancer. Curr Probl Cancer 2015; 39: 126-36
Diorio GJ, Giuliano AR. The role of human papilloma virus in penile carcinogenesis and preneoplastic lesions: a potential target for vaccination and treatment strategies. Urol Clin North Am 2016; 43: 419-25
Hakenberg OW, Compérat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015; 67: 142-50
Graafland NM, Moonen LM, van Boven HH, van Werkhoven E, Kerst JM, Horenblas S. Inguinal recurrence following therapeutic lymphadenectomy for node positive penile carcinoma: outcome and implications for management. J Urol 2011; 185: 888-93
Chipollini J, Necchi A, Spiess PE. Outcomes for patients with node-positive penile cancer: impact of perioperative systemic therapies and the importance of surgical intervention. Eur Urol 2018; 74: 241-2
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-4
Soodana-Prakash N, Koru-Sengul T, Miao F et al. Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer. Urol Oncol 2018; 36: 471.e19-27
Joshi SS, Handorf E, Strauss D et al. Treatment trends and outcomes for patients with lymph node-positive cancer of the penis. JAMA Oncol 2018; 4: 643-9
Woldu SL, Ci B, Hutchinson RC et al. Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: a propensity-score matched analysis. Urol Oncol 2018; 36: 159.e7-17
Spiess PE, Hernandez MS, Pettaway CA. Contemporary inguinal lymph node dissection: minimizing complications. World J Urol 2009; 27: 205-12
Ravi R. Morbidity following groin dissection for penile carcinoma. Br J Urol 1993; 72: 941-5
Leone A, Diorio GJ, Pettaway C, Master V, Spiess PE. Contemporary management of patients with penile cancer and lymph node metastasis. Nat Rev Urol 2017; 14: 335
Nabavizadeh R, Master V. Minimally invasive approaches to the inguinal nodes in cN0 patients. Curr Opin Urol 2019; 29: 165-72
Johnson TV, Hsiao W, Delman KA, Jani AB, Brawley OW, Master VA. Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program. Cancer 2010; 116: 2960-6
Li ZS, Yao K, Chen P et al. Disease-specific survival after radical lymphadenectomy for penile cancer: prediction by lymph node count and density. Urol Oncol 2014; 32: 893-900
Ball MW, Schwen ZR, Ko JS et al. Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. Investig Clin Urol 2017; 58: 20-6
Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol 2005; 173: 816-9
McDougal WS. Carcinoma of the penis: improved survival by early regional lymphadenectomy based on the histological grade and depth of invasion of the primary lesion. J Urol 1995; 154: 1364-6
Lemieux A, Kedarisetty S, Raju S, Orosco R, Coffey C. Lymph node yield as a predictor of survival in pathologically node negative oral cavity carcinoma. Otolaryngol Head Neck Surg 2016; 154: 465-72
Crozier J, Papa N, Perera M et al. Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma. Investig Clin Urol 2017; 58: 416-22
Wang Y, Zhou M, Yang J et al. Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Med 2019; 1: 1-11
Hegarty PK, Kayes O, Freeman A, Christopher N, Ralph DJ, Minhas S. A prospective study of 100 cases of penile cancer managed according to European Association of Urology guidelines. BJU Int 2006; 98: 526-31
Lughezzani G, Catanzaro M, Torelli T et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J Urol 2014; 191: 977-82
Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006; 93: 133-8
Lopes A, Bezerra AL, Serrano SV, Hidalgo GS. Iliac nodal metastases from carcinoma of the penis treated surgically. BJU Int 2000; 86: 690-3
Srinivas V, Morse MJ, Herr HW, Sogani PC, Whitmore WF Jr. Penile cancer: relation of extent of nodal metastasis to survival. J Urol 1987; 137: 880-2
Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol 2009; 55: 1075-88
Nicolai N, Catanzaro M, Zazzara M. The role of surgery in metastatic squamous cell carcinoma of the penis. Curr Opin Urol 2016; 26: 596-601
The Institute of Cancer Research. Available at: https://www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/clinical-trials/inpact. Accessed February 2019.

Auteurs

Juan Chipollini (J)

The University of Arizona College of Medicine, Tucson, AZ, USA.

Mounsif Azizi (M)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Salvatore Lo Vullo (S)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Luigi Mariani (L)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Yao Zhu (Y)

Fudan University Shanghai Cancer Center, Shanghai, China.

Ding W Ye (DW)

Fudan University Shanghai Cancer Center, Shanghai, China.

Antonio Augusto Ornellas (AA)

Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil.

Nick Watkin (N)

NHS Foundation Trust, St. George's University Hospitals, London, UK.

Michael Ager (M)

NHS Foundation Trust, St. George's University Hospitals, London, UK.

Oliver Hakenberg (O)

University Hospital Rostock, Rostock, Germany.

Axel Heidenreich (A)

Universitätsklinikum Köln, Köln, Germany.

Daniele Raggi (D)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Mario Catanzaro (M)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Paulo Ornellas (P)

Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil.

Roberto Salvioni (R)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Salim K Cheriyan (SK)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Andrea Necchi (A)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Phillippe E Spiess (PE)

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH